C21 BioVentures Showcases a Host of Investment Opportunities; Investors Benefit from Discounted Delegate Fees.

SANTA CRUZ, Calif. -- This year's 8th Annual C21 BioVentures conference (C21), hosted by BayBio and the National Venture Capital Association (NVCA), will be held from May 23-25 in Monterey, California. With over 250 delegates now registered to attend, C21 brings together the world's leading life science business groups in one investment conference to provide the perfect forum for investors to meet and review a host of promising private and public biotechnology companies from the US, Europe and Asia. C21 has a reduced registration rate for institutional investors. See http://www.techvision.com/c21/registration/ for further registration information.

Fifty-four mostly private life science companies, all of whom possess a unique product pipeline or technology platform, have been selected to offer 14-minute podium presentations on their funding and partnering objectives. Participating companies represent a wide range of therapeutic areas from cancer and the central nervous system to metabolic diseases and nanobiotech, and will present in 9 separate, non-concurrent presentation streams over the course of two days. As well as attending these presentations, investors can also meet companies of interest by using the online meeting scheduling system www.biopartnering.com in advance, or through the many informal networking opportunities offered at C21.

Anand Govindaluri, Associate Director, Direct Investments at Temasek Holdings in Singapore, commented, "As a life sciences investor from Southeast Asia, getting access to quality deal-flows in the US which eventually materialize into a meaningful investment has always been a challenge. But, after attending my first C21 BioVentures conference in 2001, I realized that the hit rate between a VC and a good emerging private life sciences company was excellent. C21 BioVentures presents valuable opportunities for deal flows where investors get to meet potentially good biotech companies and interact with top-tier life science investors."

Technology Vision Group LLC, producer of C21 BioVentures, has invited a group of leading venture capitalists, investment fund and asset managers, investment bankers and equity analysts to participate in C21's Advisory Board. Their expertise and leadership ensures that C21's program reflects current thinking and trends in profitable biotechnology investment strategies.

Highlights of this year's conference include leadership sessions and trends and issues sessions moderated by leading executives and key decision makers in the life science and investment industries. One such session, "VC Survivor: What it Takes to Stay in the Game" will be chaired by Cooley Godward LLP and feature speakers from Skyline Ventures, SV Life Sciences, Alloy Ventures, and Venrock Associates. The panel of seasoned venture capitalists will discuss the travails of the past few years, in a difficult financing climate, as they try to build successful lifescience companies and explain how they have managed to stay in the game.

For more information on registering for C21 BioVentures, please visit the conference website: http://www.techvision.com/c21/

Confirmed Presenting Companies:

Actimis Pharmaceuticals, Adnavance Technologies, Ambit Biosciences, Amcyte, Amkor Pharma, Inc., Aquinox Pharmaceuuticals Inc., Aragen BioSciences, Astex Therapeutics Ltd., Athenagen, Avera Pharmaceuticals Inc., Avidia, Inc., BioSeek, Inc., Borean Pharma A/S, Clera Inc., Colby Pharmaceuticals, Cumbre Phamaceuticals Inc., Cylene Pharmaceuticals Inc., DiObex, Evolva SA, F2G Limited, Genetix Pharmaceuticals, Inc., iCo Therapeutics Inc., immatics, Inimex Pharmaceuticals, Inc., KAI Pharmaceuticals Inc., Kemia, Inc., Kinexis, Inc., Lymphosign Inc., Nanospectra Biosciences, Nerites Corporation, Neugenesis Corporation, NeuroTherapeutics Pharma, Novasite Pharmaceuticals, Nura Inc., ODC Therapy, Orexigen Therapeutics, Inc., PIramed Ltd, Pivotal BioSciences Inc., PLx Pharma Inc., PolyMedix Inc., Prolexys Pharmaceuticals, Inc., Quintessence Biosciences, Rincon Pharmaceuticals, Inc., Saegis Pharmaceuticals, Inc., Sapphire Therapeutics, Inc., SkinMedica, Inc., Taligen Therapeutics, Theregen, Inc., TransOral Pharmaceuticals, Inc., Trellis Bioscience, Inc., Twinstrand Therapeutics Inc., Viventia Biotech Inc., Xenome Ltd., XYTIS Inc.

Advisory Board

3i plc, A. M. Pappas & Associates, LLC, Alloy Ventures, Alta Partners, Atlas Venture, BioMedinvest AG, Delphi Ventures, Domain Associates, DVC Deutsche Venture Capital, Earlybird Venture Capital, Enterprise Partners, Equity4Health, LLC, EuclidSR Partners, Ferghana Partners Group, Forward Ventures, Frazier Healthcare Ventures, Hamilton BioVentures, Index Ventures, Intersouth Partners, InterWest Partners, Investor Growth Capital, JP Morgan Partners, Kleiner Perkins Caufield & Byers, Lehman Brothers, New Leaf Venture Partners, LLC, Perseus-Soros BioPharmaceutical Fund, PiperJaffray Ltd, Prism Venture Partners, Prospect Venture Partners, Quest Management NV, Sanderling Ventures VI, L.P., Science Futures, Inc., Skyline Ventures, Sofinnova Ventures, SV Lifesciences, Techno Venture Management, Technology Vision Group LLC, TPG Ventures, Versant Ventures, Warburg Pincus

Conference Sponsors

Alexandria Real Estate Equities, BayBio, Burrill & Company, CIBC World Markets, Comerica, Cooley Godward LLP, Deloitte, Earlybird, Ferghana Partners Group, Life Science Analytics, Inc., NVCA, Prism Venture Partners, Sanderling Venture Capital, Silicon Valley Bank, Solomon-Page Group, Square 1 Bank, SV Life Sciences, TVM Capital

Conference Supporters

BioCentury Publications, Business Wire, Citigate, Life Science Angels, Red Herring, Tenex Medical, Inc.